1AD AdAlta Limited
Healthcare · Biotechnology
· website
· 2 employees
$0.00
52wk 0.00 – 0.01
Overall
29.5
Value
76.9
Growth
0.0
Health
13.9
Quality
0.0
Momentum
55.8
Dividend
—
Price
About AdAlta Limited
AdAlta Limited, a clinical-stage biotechnology company, develops cellular immunotherapies for the treatment of solid cancers in Australia. The company also commercializes protein therapeutics. In addition, it engages in the development of AD-21, a protein therapeutic for fibrotic diseases, including lung fibrosis and kidney fibrosis in Phase 1 clinical studies; and WD-34, a discovery stage i-body for the treatment and prevention of malaria and related diseases. The company was incorporated in 2006 and is based in Hawthorn East, Australia.
Price analytics
Returns
| 1 day | 0.0% |
| 1 week | 14.3% |
| 1 month | 0.0% |
| 3 months | 0.0% |
| 6 months | 0.0% |
| 1 year | 100.0% |
| 3 years | -77.3% |
Risk
| Volatility (1y ann.) | 201.6% |
| Beta vs ASX 200 | 1.27 |
| Sharpe (1y) | 1.26 |
| VaR 95% (1-day) | -16.7% |
| Max drawdown (1y) | -57.1% |
| Off 1-year high | -42.9% |
Technicals
| RSI(14) | 67 |
| vs 50DMA | 19.4% |
| vs 200DMA | 0.1% |
| Trend | Death cross |
Fundamental trends
Financial statements
Loading…
Scoring breakdown
(2 Oct 2026)
Value
76.9
Trailing P/E
—
Forward P/E
100
PEG ratio
—
EV / EBITDA
100
Price / Book
—
Price / Sales
0
Growth
0.0
Revenue growth (1y)
0
Revenue CAGR (3y)
—
EPS growth (1y)
—
EPS CAGR (3y)
—
Financial Health
13.9
Net debt / EBITDA
—
Interest coverage (EBIT/interest)
0
Current ratio
28
Debt / Equity
—
Quality (Profitability & Cash Flow)
0.0
Return on equity
—
Return on assets
0
Operating margin
0
Net margin
0
Cash conversion (OCF / net income)
—
Dividend / Income
—
No meaningful dividend — pillar excluded from the overall score.
Momentum
55.8
6-month return vs ASX 200
46
Price vs 200-day average
50
Price vs 50-day average
100
Position in 52-week range
33
Hover a row's info icon for the exact rule. Bounds and weights are configurable in the Django admin (Scoring configuration).
Score history
Key metrics
Market cap
$12.85M
P/E (trailing)
—
P/E (forward)
-0.13
EPS (trailing)
0.00
Dividend yield
—
Payout ratio
0.0%
Beta
0.19
EV / EBITDA
-2.68
Price / Book
—
ROE
—
Operating margin
-2,251.0%
Net margin
0.0%
Total cash
$1.28M
Total debt
$0
Current ratio
1.27
Debt / Equity
—
Free cash flow
$-2.03M
Avg volume
1.50M
Latest annual results
(FY ending 30 Jun 2026)
- Revenue—
- Gross profit—
- Operating income-$4.80M
- Net income-$4.68M
- Diluted EPS-0.00
- Free cash flow-$4.44M
- Net debt-$1.28M